tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Archive for 'Trading News'

New Age Farm Inc. Growing Fundamentals with Revenue-Producing Portfolio in U.S., Canada, and South American Cannabis Markets

New Age Farm Inc. Growing Fundamentals with Revenue-Producing Portfolio in U.S., Canada, and South American Cannabis Markets

Written by Ι Stock Market Media — October 11, 2018

New Age Farm Inc. (OTC Markets: NWGFF) (CSE: NF) (FSE: 0NF) is growing quickly in the Cannabis industry, and it’s doing so by focusing on the fundamentals.  The Denver-based company is meticulously carving out its share of the emerging hemp and CBD markets in the U.S., Canada and South America. And, in the process, it’s providing the cannabis space with more choices while offering investors an opportunity to get in on the ...

Read More →
0

PUF Ventures Bringing Science of Plant Propagation to Medical and Recreational Cannabis Industry

PUF Ventures (CNW Group/PUF Ventures)

Written by Ι Stock Market Media — July 31, 2018

In an effort to differentiate itself from the emerging cannabis market in Canada, PUF Ventures Inc. (OTCPK: PUFXF) (CSE: PUF) (Frankfurt: PU3) has taken a novel approach to producing cannabis that should prove to be every bit as lucrative as growing it. With the idea of separating itself from the competition in mind, the innovative Vancouver-based company partnered with Casey Houweling, who has 4 decades of experience with plant propagation, to form ...

Read More →
0

BLOX Labs Using Blockchain Technology to Compete in Canada’s Cannabis Industry with Supply Chain Management Platform

BLOX Labs Using Blockchain Technology to Compete in Canada’s Cannabis Industry with Supply Chain Management Platform

Written by Ι Stock Market Media — July 11, 2018

BLOX Labs Inc. (OTCMKTS: BLLXF) (CSE: BLOX) (Frankfurt: BR1B), a Toronto-based technology development company focused on creating best-in-class software solutions driven by emerging trends in blockchain, smart contracts and decentralized apps, has ideally positioned itself to be a player in Canada’s legal cannabis industry. It’s an industry that just got a huge shot in the arm with last month’s legalization of marijuana nationwide. In Canada, marijuana possession, home growing, and sales of ...

Read More →
0

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

Written by Ι Stock Market Media — June 6, 2018

PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA).  It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...

Read More →
0

PharmaCyte Biotech CEO & CSO Interview – Discussion of IND, Cell Encapsulation, Clinical Trial Design, CRO, and More

PharmaCyte Biotech CEO & CSO Interview – Discussion of IND, Cell Encapsulation, Clinical Trial Design, CRO, and More

Written by Ι Stock Market Media — May 30, 2018

Today Stock Market Media Group is releasing its latest Interview in our series of CEO Interviews.  Today we welcome PharmaCyte Biotech (OTCQB: PMCB) a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, and the company’s Chief Executive Officer, Kenneth L. Waggoner, and its Chief Scientific Officer, Prof. Walter H. Günzburg.

Click Here to Listen ...

Read More →
0

PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

Written by Ι Stock Market Media — May 21, 2018

PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application (IND) to the U.S. FDA.  It’s an IND that has been eagerly anticipated by the company’s shareholders since PharmaCyte met with the FDA in early 2017, and it would lay out PharmaCyte’s planned Phase 2b clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC.

The key ...

Read More →
0
Page 1 of 31 12345...»
ContactUs.com